Skip Navigation


European Heart Journal Advance Access originally published online on March 10, 2009
European Heart Journal 2009 30(7):750-751; doi:10.1093/eurheartj/ehp065
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
30/7/750    most recent
ehp065v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tamburino, C.
Right arrow Articles by Capodanno, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tamburino, C.
Right arrow Articles by Capodanno, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

Pursuing the goal to improve downstream myocardial tissue perfusion

Corrado Tamburino* and Davide Capodanno

Department of Cardiology, Ferrarotto Hospital, University of Catania, 95124 Catania, Italy

* Corresponding author. Tel: +39 0957436201, Fax: +39 095362429, Email: tambucor@unict.it

This editorial refers to ‘Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon’{dagger}, by Y. Kawai et al., on page 765

The first 10% of the full text of this article appears below.

The coronary slow flow phenomenon is an angiographic finding characterized by delayed distal vessel opacification in the absence of significant epicardial coronary disease. Extensively studied both in the experimental and clinical setting, it was clearly associated with unfavourable clinical outcome and prognosis.1,2 Several hypotheses, including embolization of platelet-rich thrombi or atherosclerotic plaque debris that can ‘sludge’ the distal vessel, and release of vasoconstrictive substances causing intense vasospasm of the distal microcirculation, were advocated to justify this event in the context of percutaneous coronary intervention.

If the principal mechanism of the slow flow phenomenon is vasoconstriction, this would explain the favourable response seen with intracoronary administration of calcium antagonists such as verapamil, or vasodilators such as nitroprusside, papaverine, and adenosine.

Nicorandil, a nicotinamide ester, is a vasodilator agent approved . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon
Yusuke Kawai, Kenichi Hisamatsu, Hiromi Matsubara, Kazuhiro Dan, Satoshi Akagi, Katsumasa Miyaji, Mitsuru Munemasa, Yoshihisa Fujimoto, Kengo F. Kusano, and Tohru Ohe
EHJ 2009 30: 765-772. [Abstract] [Full Text]